Endo sued the FDA three months later, hoping to hasten the agency's actions.Įndo's adamant plea to the FDA was prefaced by claims of increased patient safety with the crush-resistant formulation of Opana ER. The company strongly urged the FDA to keep the generic formulation of the original Opana ER off the market, citing a massive increase in abuse of Opana ER following the marketing of a crush-resistant formulation of Ox圜ontin. The Case For Fraud: Opana ERīelow is a timeline of the major events surrounding Endo and Opana ER.Įndo went through great lengths to prove that the old version of Opana ER was too dangerous for the market, but not before marketing the new, crush-resistant formulation for nearly a year. The company complied with the FDA's historical request for removal from the market of Endo's oxymorphone-based Opana ER in June of last year. Thus far, Endo has not admitted any wrongdoing and has appeared cooperative in the very early stages of litigation. Endo said it will cooperate in giving the requested information in the subpoena.Įach lawsuit claims that Endo used fraudulent marketing and falsified research surrounding the addictive properties of their oxymorphone based drug, Opana ER, in order to drive sales. Most recently, the Southern District of Florida filed a grand jury subpoena demanding Endo's "documents & information relating to products containing oxymorphone". Over ten states, cities, and counties have already filed lawsuits against the company, with more likely to come. Opioid LitigationĮndo Pharmaceuticals is facing litigation from counties and states all over the nation. Investors should refrain from going long on Endo until there is a better indication of the outcome of the lawsuits. Endo stands out amongst the other pharmaceutical companies being sued, and is much more likely to face detrimental consequences. Meet the Professor & Meet the ScientistDiscover insights from experts on treating a variety of endocrine conditions and emerging science in the field of endocrinology, and learn the latest in patient care and scientific research.Endo Pharmaceuticals ( ENDP) rapidly became a primary target of litigation filed by over a dozen U.S.
These special “meeting-within-a-meeting” tracks integrate focused discussions, poster sessions, and networking opportunities to provide you with the latest research in: Listen, learn, and be inspired by world-class faculty who are at the forefront of scientific discovery and high-quality health care. Our ENDO 2022 lineup of sessions offers a unique opportunity to dive into topics from nearly every major therapeutic area of endocrinology and hormone science. Spanning the spectrum of science, clinical care, and social implications, an outstanding slate of world-renowned speakers will showcase the most cutting-edge advances on research and medicine. Product theaters and the Communications and Career Center will also include hybrid content delivery. We will have over 200 hours available on demand for Standard and Premium pass registrants. In addition, our in-person and livestreamed sessions will be recorded, so you can access them on demand after 72 hours. These sessions are being livestreamed, so they are available in real time to our virtual audience. What Programming Is Included in My Virtual Meeting Registration?Īs you build your schedule during the conference, you can select the sessions that are tagged with 'Livestreamed', so you can view virtually.
more than 100 in-person and virtual sessions with another 70+ in-person only sessions.
ENDO PHARMA SLALOM PDF
Download the PDF Program and Meeting Guide. ENDO’s comprehensive program provides attendees the opportunity to learn about the latest developments in hormone science and medicine from renowned investigators, expert clinicians, and educators from all over the world.
0 kommentar(er)
